Oravax to focus on oral COVID-19 vaccine 

Premas Biotech (Gurugram, India) and Oramed Pharmaceuticals (Jerusalem) have announced that they are developing an oral COVID-19 vaccine that has shown efficacy after a single dose in animals.

To accelerate the development of the vaccine, the two companies have created a joint venture known as Oravax Medical.

The availability of effective single-dose oral COVID-19 vaccines could go far in simplifying logistics.

Supply chain challenges have hampered mass vaccination campaigns in many parts of the world. Many coronavirus vaccines require two doses and several require uncommonly cold storage temperatures.

“An oral COVID-19 vaccine would eliminate several barriers to rapid, wide-scale distribution, enabling people to take the vaccine themselves at home,” said Nadav Kidron, CEO of Oramed in a statement. “While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the likely case tha…

Read more
  • 0

Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech

Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines.

New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0